RAD51 and cancer: A single nucleotide polymorphism in the 5′-untranslated region (5′-UTR) of RAD51 (a G to C substitution at position 135, the G/C polymorphism) can influence cancer risk among BRCA1/BRCA2 mutation carriers [10], [11].